This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular system in the initial report submitted to the fda on (b)(6) 2015.(b)(4).Visual inspection was performed on the returned sample, during which no anomalies were noted anywhere on the device.Ops valves are subject to a 100% leak test, which includes five different tests the units are run through to ensure there are no leaks and both the umbrellas and duckbills are functioning properly.The returned sample was manually run through each of these tests to determine if the umbrellas were functioning properly and not allowing air to enter the valve.No leaks occurred during any of the five tests, and the device met specifications.A review of the device history record revealed no indication of production related anomalies.The complaint was not confirmed.From the information received by the customer, the returned sample was not utilized in the vent line, as intended.A definitive root cause could not be determined, but the reported entrainment of air experienced is likely due to the use of the valve in the hemoconcentrator line and other unknown clinical conditions.(b)(4).All available information has been placed on file in quality management for appropriate tracking, trending and follow up.
|